OncoMatch/Clinical Trials/NCT07097363
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Is NCT07097363 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for b-cell non-hodgkin lymphoma.
Treatment: Cyclophosphamide · Doxorubicin · Epcoritamab · Etoposide · Prednisone · Rituximab — This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that can bind to two different antigens at the same time. Epcoritamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. The EPOCH-R is administrated as the standard of care treatment. This may help the immune system kill cancer cells. Giving epcoritamab with EPOCH-R may be safe, tolerable, and effective in treating patients with aggressive B-cell non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Hodgkin Lymphoma
Biomarker criteria
Allowed: MYC translocation
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Allowed: BCL2 translocation
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Allowed: BCL6 translocation
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Allowed: EBV positive
Epstein Barr virus (EBV) + DLBCL, NOS
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy for lymphoma
Exception: 1 prior cycle of chemoimmunotherapy allowed; prior radiotherapy allowed if not used as measurable site; steroids for symptom control allowed as specified
Prior systemic treatment for lymphoma. Prior radiotherapy is allowed provided that this site is not used as a measurable site to assess response. A maximum of 1 cycle of chemoimmunotherapy is allowed if needed for urgent disease stabilization if patient had staging PET/CT and LVEF evaluation prior to chemoimmunotherapy
Cannot have received: systemic therapy for indolent lymphoma
Prior systemic therapy for indolent lymphoma
Cannot have received: organ transplantation
Prior organ transplantation
Lab requirements
Blood counts
ANC ≥ 1,000/μL except in cases of marrow infiltration by lymphoma; Platelets ≥ 75,000 / mcL except in cases of marrow infiltration by lymphoma or hypersplenism; Hemoglobin ≥ 8 g/dL except in cases of marrow infiltration by lymphoma without RBC transfusion within 14 days of first treatment
Kidney function
Measured or calculated creatinine clearance (or GFR) ≥ 45 mL/min
Liver function
Serum total bilirubin ≤ 1.5 X ULN (≤ 3.0 x ULN if Gilbert disease) OR direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 ULN; AST and ALT ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver involvement
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50% on MUGA or ECHO
LVEF ≥ 50% on cardiac MUGA or ECHO; ANC ≥ 1,000/μL except in cases of marrow infiltration by lymphoma; Platelets ≥ 75,000 / mcL except in cases of marrow infiltration by lymphoma or hypersplenism; Hemoglobin ≥ 8 g/dL except in cases of marrow infiltration by lymphoma without RBC transfusion within 14 days of first treatment; Creatinine clearance (or GFR) ≥ 45 mL/min; Serum total bilirubin ≤ 1.5 X ULN (≤ 3.0 x ULN if Gilbert disease) OR direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 ULN; AST and ALT ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify